BioStock

Prenumeration

Annexin gets green light for phase IIa study in diabetic retinopathy

2025-08-13 10:55:00

Annexin Pharmaceuticals has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a phase IIa clinical trial with the drug candidate ANXV for the treatment of diabetic retinopathy (DR). As part of the preparations for a future phase IIb trial, patients with newly diagnosed retinal vein occlusion (RVO) will also be included. The aim of the RVO part of the study is to evaluate a shorter treatment cycle than previously requested by potential licensees.

Read the article at biostock.se:

https://biostock.se/en/2025/08/annexin-far-gront-ljus-for-fas-iia-studie-inom-diabetesretinopati/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook! 

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

BioStock

Prenumeration

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden